Page 6 - Exscientia News Today

Exscientia (NASDAQ:EXAI – Get Rating) had its target price trimmed by Morgan Stanley from $15.00 to $14.00 in a report released on Monday, Benzinga reports. The firm currently has an equal weight rating on the stock. Exscientia Stock Performance NASDAQ EXAI opened at $5.31 on Monday. Exscientia has a twelve month low of $4.09 and […]

Exscientia (NASDAQ:EXAI – Get Rating) and X4 Pharmaceuticals (NASDAQ:XFOR – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, dividends, earnings, valuation and risk. Analyst Recommendations This is a breakdown of current recommendations and […]

Exscientia plc (NASDAQ:EXAI – Get Rating) shares shot up 3.2% during trading on Wednesday . The stock traded as high as $5.20 and last traded at $5.20. 8,853 shares changed hands during mid-day trading, a decline of 97% from the average session volume of 289,077 shares. The stock had previously closed at $5.04. Exscientia Stock […]

Exscientia plc (NASDAQ:EXAI – Get Rating)’s stock price dropped 5.8% on Thursday . The company traded as low as $5.25 and last traded at $5.32. Approximately 100,223 shares traded hands during trading, a decline of 66% from the average daily volume of 295,813 shares. The stock had previously closed at $5.65. Exscientia Price Performance The […]

Exscientia plc Recent developments in the Company’s pipeline, collaborations, and operations as well as financial results for the fourth quarter and full year 2022 are summarised below.... | March 23, 2023

Company to host conference call and webcast on March 23, 2023 at 12:30 p.m. GMT 8:30 a.m. EDT Exscientia plc (Nasdaq: EXAI) will report financial results for the fourth quarter and full year ended

- Abstracts highlight pipeline programmes in precision oncology, including novel LSD1 inhibitor - Further detail on A2A programme, including novel biomarker for patient selection to be presented

15.03.2023 - Exscientia plc (Nasdaq: EXAI) today announced that four abstracts have been accepted for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, being held April 14-19, 2023, at the Orange County ... Seite 1

Precision designed LSD1 and MALT1 inhibitors currently progressing through IND-enabling studies Both molecules demonstrate Exscientia's ability to overcome critical design challenges and identify

Partnership will further validate Exscientia's functional drug testing platform to predict response in haematological cancers - Exscientia plc (Nasdaq: EXAI) today announced a new collaboration with